Orange Book product · Brand (NDA)
ZARONTIN
ETHOSUXIMIDE
At a glance
Approved Prior to Jan 1, 1982
Approved
Brand (NDA)
Application
AB
TE code
None
Listed patents
Key dates
No patent or exclusivity dates are listed for this product.
Pharmaceutical detail
Active ingredient
ETHOSUXIMIDE
Strength
250MG
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
NDA 012380
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2020ETHOSUXIMIDEGeneric (ANDA)
ANDA 210654 · PURACAP PHARM LLC
- 2019ETHOSUXIMIDEGeneric (ANDA)
ANDA 211928 · ONESOURCE SPECIALTY
- 2012ETHOSUXIMIDEGeneric (ANDA)
ANDA 200892 · HERITAGE PHARMS INC
- 2008ETHOSUXIMIDEGeneric (ANDA)
ANDA 040686 · EPIC PHARMA LLC
- 2003ETHOSUXIMIDEGeneric (ANDA)
ANDA 040506 · CHARTWELL RX
- 2002ETHOSUXIMIDEGeneric (ANDA)
ANDA 040430 · BIONPHARMA
- 2000ETHOSUXIMIDEGeneric (ANDA)
ANDA 040253 · PHARM ASSOC
- 1993ETHOSUXIMIDEGeneric (ANDA)
ANDA 081306 · TEVA PHARMS
- —ZARONTINGeneric (ANDA)
ANDA 080258 · PARKE-DAVIS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
